These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25819175)

  • 1. Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma.
    Komatsu S; Ichikawa D; Miyamae M; Kawaguchi T; Morimura R; Hirajima S; Okajima W; Ohashi T; Imamura T; Konishi H; Shiozaki A; Ikoma H; Okamoto K; Taniguchi H; Otsuji E
    Expert Opin Biol Ther; 2015 Jun; 15(6):773-85. PubMed ID: 25819175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker.
    Goto T; Fujiya M; Konishi H; Sasajima J; Fujibayashi S; Hayashi A; Utsumi T; Sato H; Iwama T; Ijiri M; Sakatani A; Tanaka K; Nomura Y; Ueno N; Kashima S; Moriichi K; Mizukami Y; Kohgo Y; Okumura T
    BMC Cancer; 2018 Jan; 18(1):116. PubMed ID: 29385987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma.
    Imamura T; Komatsu S; Nishibeppu K; Kiuchi J; Ohashi T; Konishi H; Shiozaki A; Yamamoto Y; Moriumura R; Ikoma H; Ochiai T; Otsuji E
    BMC Cancer; 2024 Jul; 24(1):907. PubMed ID: 39069624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
    Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
    PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-10a in Pancreatic Juice as a Biomarker for Invasive Intraductal Papillary Mucinous Neoplasm by miRNA Sequencing.
    Kuratomi N; Takano S; Fukasawa M; Maekawa S; Kadokura M; Shindo H; Takahashi E; Hirose S; Fukasawa Y; Kawakami S; Hayakawa H; Takada H; Nakakuki N; Kato R; Yamaguchi T; Nakayama Y; Kawaida H; Kono H; Inoue T; Kondo T; Ichikawa D; Enomoto N
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
    Simpson RE; Yip-Schneider MT; Flick KF; Wu H; Colgate CL; Schmidt CM
    Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possibility of detecting intraductal papillary mucinous neoplasms using metabolite biomarkers for pancreatic cancer.
    Nakano R; Nishiumi S; Kobayashi T; Ikegawa T; Kodama Y; Yoshida M
    Biomark Med; 2020 Jul; 14(11):1009-1020. PubMed ID: 32940075
    [No Abstract]   [Full Text] [Related]  

  • 10. Extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasm of the pancreas: prevalence, associated factors, and comparison with patients with other pancreatic cystic neoplasms.
    Yoon WJ; Ryu JK; Lee JK; Woo SM; Lee SH; Park JK; Kim YT; Yoon YB
    Ann Surg Oncol; 2008 Nov; 15(11):3193-8. PubMed ID: 18784959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
    Abue M; Yokoyama M; Shibuya R; Tamai K; Yamaguchi K; Sato I; Tanaka N; Hamada S; Shimosegawa T; Sugamura K; Satoh K
    Int J Oncol; 2015 Feb; 46(2):539-47. PubMed ID: 25384963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intraductal papillary mucinous neoplasm of the pancreas (IPMN)--standards and new aspects].
    Distler M; Welsch T; Aust D; Weitz J; Grützmann R
    Zentralbl Chir; 2014 Jun; 139(3):308-17. PubMed ID: 24241954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
    Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
    J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN.
    Yang KS; Ciprani D; O'Shea A; Liss AS; Yang R; Fletcher-Mercaldo S; Mino-Kenudson M; Fernández-Del Castillo C; Weissleder R
    Gastroenterology; 2021 Mar; 160(4):1345-1358.e11. PubMed ID: 33301777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
    Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
    Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
    Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
    Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
    Roch AM; DeWitt JM; Al-Haddad MA; Schmidt CM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of tumor markers and biochemistry in the preoperative invasive assessment of intraductal papillary mucinous neoplasm of the pancreas.
    You L; Ma L; Zhao WJ; Zhao YP; Dai MH
    Clin Chim Acta; 2016 Feb; 454():89-93. PubMed ID: 26746574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
    Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.